Sarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow SRPT
Sarepta Therapeutics, Inc. (SRPT) Altman Z-score
Sarepta Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is −0.97, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −0.97 | (3.70) |
| FY2024 | 2.73 | 1.60 |
| FY2023 | 1.13 | (0.07) |
| FY2022 | 1.21 | 0.09 |
| FY2021 | 1.11 | (1.53) |
| FY2020 | 2.64 | (1.00) |
| FY2019 | 3.64 | (2.54) |
| FY2018 | 6.18 | 2.96 |
| FY2017 | 3.21 | (0.89) |
| FY2016 | 4.10 | (1.10) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.43 | — | 0.52 | |
| Retained earnings / total assets | (1.46) | — | −2.04 | |
| EBIT / total assets | (0.21) | — | −0.69 | |
| Market value of equity / total liabilities | 0.98 | — | 0.59 | |
| Sales / total assets | 0.66 | — | 0.66 | |
| Altman Z-score | Distress zone | −0.97 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −2.78 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ZYME Zymeworks Inc. compare | 11.6× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 8.4× |
| AGIO Agios Pharmaceuticals, Inc. compare | 8.1× |
| MESO Mesoblast Limited compare | 3.4× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 0.4× |
| SRPT Sarepta Therapeutics, Inc. | −1.0× |
| URGN Urogen Pharma compare | −5.2× |
| PVLA Palvella Therapeutics, Inc. compare | −11.5× |
| MLYS Mineralys Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets